Livanova Plc Stock Price, News & Analysis

LivaNova PLC (NASDAQ: LIVN) reported a 2.1% increase in worldwide sales for Q1 2021, totaling $247.6 million, but a decline of 0.4% on a constant-currency basis. The company experienced a diluted loss per share of $0.61 under GAAP, while adjusted diluted EPS was $0.35, up from $0.33 in Q1 2020. Notably, Neuromodulation sales rose by 15.7%, while Cardiovascular sales fell by 9.4%. For 2021, LivaNova anticipates net sales growth between 8% and 13%, reaffirming its full-year guidance.

LivaNova PLC (NASDAQ:LIVN) has received FDA 510(k) clearance for B-Capta®, an in-line blood-gas monitoring system integrated into the S5® heart-lung machine. This system enhances monitoring during cardiopulmonary bypass procedures for both adults and children, providing accurate blood gas measurements. B-Capta's features include a no-calibration setup and integration with the S5 HLM, improving workflow for perfusionists. Additionally, LivaNova announced clearance for the upgraded S5 PRO™ HLM with enhanced software and alarm systems.

LivaNova PLC (NASDAQ:LIVN) announced the randomization of the 300th patient in its ANTHEM-HFrEF Pivotal Study, aiming to evaluate Autonomic Regulation Therapy (ART) for heart failure treatment. This FDA-approved study will analyze the effectiveness of Vagus Nerve Stimulation (VNS) on symptoms and clinical outcomes in heart failure patients with reduced ejection fraction. The VITARIA System, designed for ART delivery, may become a first-in-class device if approved. Notable clinical outcomes include symptom relief and reduced hospitalizations.

LivaNova PLC (NASDAQ:LIVN), a leader in medical technology, will host a conference call on April 28, 2021, at 12 p.m. London time (7 a.m. EDT) to discuss its Q1 2021 results. The results will be released prior to the call. Interested listeners can access a live audiocast via the Investors section of LivaNova's website. The dial-in numbers include 844-558-0159 for U.S. and Canada and 236-714-3182 for other regions, with a conference ID of 6493742. A replay will be available for 90 days following the call.

LivaNova PLC (NASDAQ: LIVN) reported a Q4 2020 revenue of $269.6 million, a 6.3% decline compared to Q4 2019, impacted by COVID-19. The diluted loss per share was $5.74, while adjusted EPS was $0.71. Cardiovascular sales fell by 10.1%, with Heart Valves down 27.2%, but Advanced Circulatory Support saw a 50.3% increase. For FY 2020, total sales decreased by 13.8% to $934.2 million. Looking ahead, LivaNova forecasts 2021 sales growth of 8-13% and adjusted EPS between $1.40 and $1.90, despite ongoing COVID-related uncertainties.

LivaNova PLC (NASDAQ:LIVN) will hold a conference call on February 24, 2021, at 1 p.m. London time (8 a.m. EST) to discuss its fourth quarter and full-year 2020 results, which will be released prior to the call. Interested parties can access a live audiocast on LivaNova's Investor Relations website. For phone access, dial 844-239-5285 or 512-961-6524, using conference ID 1290829. A replay will be available for 90 days post-call. LivaNova is a global medical technology company dedicated to innovative healthcare solutions, serving over 100 countries.

LivaNova PLC (NASDAQ:LIVN) will host a virtual symposium titled "Updates and Advances in Neuromodulation" at AES2020 on December 6, 2020, from 6 to 8:30 p.m. ET. The event will feature leading clinicians discussing the role of VNS Therapy in treating drug-resistant epilepsy (DRE) and other disorders. Attendees will explore the economic and healthcare burdens of DRE and learn how VNS Therapy can alleviate these challenges. The symposium is free for AES2020 registrants, and a recording will be available afterward.

LivaNova PLC (NASDAQ:LIVN) has announced a strategic divestiture of its heart valve (HV) business to Gyrus Capital for an enterprise value of €60 million (US$73 million). The deal, unanimously approved by LivaNova's Board of Directors, aims to enhance focus on neuromodulation and cardiovascular platforms. The transaction is expected to be dilutive to earnings per share by approximately 10-15 cents in 2021 and may trigger a non-cash impairment charge of US$200 million to US$225 million. Completion is targeted for the first half of 2021, pending regulatory approvals.

LivaNova PLC (NASDAQ:LIVN) announced that CEO Damien McDonald will speak at the Berenberg European Conference 2020 on December 2 at 4 p.m. GMT. Attendees should log in 10 minutes early to prepare for the audiocast. A replay will be available on LivaNova's website within 24 hours for 90 days. Established nearly 50 years ago, LivaNova is a leading global medical technology company focused on innovative solutions for patients’ heart and brain health, employing around 4,000 people across more than 100 countries.